Results 91 to 100 of about 31,435 (210)
Alimentary Pharmacology &Therapeutics, EarlyView.In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi +8 more
wiley +1 more source
Middle East Fertility Society Journal, 2016 Objective: To evaluate the efficacy of letrozole in the endometrial preparation of vitrified–warmed embryo transfer cycles and to compare it to the hormonal preparation with estradiol valerate and progesterone study.
Hoda Sibai +2 more
doaj +1 more source
Breast Cancer Research, 2020 Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer.
Swaathi Jayaraman +21 more
doaj +1 more source
The Relationship Between Polycystic Ovary Syndrome (PCOS) and Depression
Clinical Endocrinology, EarlyView.ABSTRACT Objective Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder, frequently accompanied by psychological comorbidities including depression. The aim of this narrative review is to summarise the latest research regarding potential contributors to and underpinning mechanisms of this relationship.
Asimina I. Karampela, Maralyn Druce
wiley +1 more source
Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by β Amyloid
Journal of Aging Research, 2013 Reduced estrogens, either through aging or postsurgery breast cancer treatment with the oral nonsteroidal aromatase inhibitor letrozole, are linked with declined cognitive abilities.
P. K.-Y. Chang +3 more
doaj +1 more source
The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer [PDF]
, 2017 Aims: Although the role of phosphorylation of oestrogen receptor (ER) at serines 118 (p-S118) and 167 (p-S167) has been studied, the relationship between p-S118, p-S167 and the tumour microenvironment in ER-positive primary operable ductal breast ...
Arnold +38 more
core +1 more source
International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching +20 more
wiley +1 more source
Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels [PDF]
, 2015 BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause.
Lamond, Nathan W D +3 more
core +1 more source
American Journal of Medical Genetics Part A, Volume 200, Issue 6, Page 1452-1457, June 2026.ABSTRACT FOXA2 (hepatocyte nuclear factor‐3β, HNF‐3β) encodes a transcriptional activator involved in early embryogenesis, particularly in the patterning and differentiation of midline structures such as the neural tube, foregut, and pituitary gland. Its role in human pathogenesis was first suspected when patients with deletion of chromosome 20p11.2 ...
Christopher Connolly +3 more
wiley +1 more source
Cancer Innovation, Volume 5, Issue 3, June 2026.The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao +12 more
wiley +1 more source